On the 24th, Lotte Biologics announced that it has signed a production contract for antibody-drug conjugate (ADC) candidates for clinical trials with a Asia-based biotech company.
With this contract, Lotte Biologics plans to fully operate its ADC production facility, which has been expanded since 2023 at the Bio Campus in Syracuse, New York. The company aims to provide contract development and manufacturing organization (CDMO) services for ADCs that meet the diverse needs of clients from clinical development stages to commercial production.
Recently, a ceremony was held to celebrate the completion of the ADC production facility, attended by James Park, CEO of Lotte Biologics, and Shin Yoo-yeol, head of the global strategy office at Lotte Biologics. The company plans to secure additional clients and expand partnerships starting with this order.
According to Lotte Biologics, the ADC production facility, which was invested in with approximately $100 million (143 billion won), has received cGMP (current Good Manufacturing Practices) certification. It includes an integrated production and purification line with a maximum of 1,000-liter (L) conjugation reactors, and it offers its own quality control (QC) testing and characterization analysis services. The facility has introduced a single-use system, which is used once and discarded, responding to a wide range of client requirements from antibody pretreatment processes to automated sterile filling of raw materials.
James Park, CEO of Lotte Biologics, noted, "With this contract, we will reliably supply high-quality ADC pharmaceuticals and solidify our position as a contract manufacturing organization that includes not just antibodies but also ADCs in the global market," adding that he plans to actively seek collaboration opportunities to enhance the competitiveness of the ADC modality business.